In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: A nationwide population-based study

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Ho, Te Wei ^a   Tsai, Yi Ju ^b   Ruan, Sheng Yuan ^c   Huang, Chun Ta ^a,c   Lai, Feipei ^a   Yu, Chong Jen ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; AGED; ARTICLE; ARTIFICIAL VENTILATION; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; INTENSIVE CARE; LENGTH OF STAY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; POPULATION BASED CASE CONTROL STUDY; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; RISK REDUCTION; ADULT; COMORBIDITY; DISEASE COURSE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITAL MORTALITY; HOSPITALIZATION; LONGITUDINAL STUDY; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TAIWAN; TIME FACTOR; TRENDS;

ADULT; AGED; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TAIWAN; TIME FACTORS;

EID: 84918586737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114866     Document Type: Article

References (48)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347-365.
2. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, et al. (2006) Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 27: 397-412.
3. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA (2005) Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 446-452.
4. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, et al. (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1418-1422.
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, et al. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60: 925-931.
6. Singanayagam A, Schembri S, Chalmers JD (2013) Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc 10: 81-89.
7. Suissa S, Dell'Aniello S, Ernst P (2012) Long-term natural history of chronic obstructive pulmonary disease: Severe exacerbations and mortality. Thorax 67: 957-963.
8. Ministry of health and Welfare, Taiwan: 2012 public health annual report. Available: Http://www.mohw.gov.tw/EN/Ministry/DM2-P.aspx?f-list-no5475&fod-list-no5853&doc-no529943. Accessed 2014 Jul 31.
9. National Health Institutes, Taiwan: Introduction to National Health Insurance Research Database. Available: Http://nhird.nhri.org.tw/en/index.htm. Accessed 2014 Jul 31.
10. Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, et al. (2002) Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 122: 1264-1270.
11. Gil A, Gil R, Oyaguez I, Carrasco P, Gonz Lez A (2006) Hospitalization by pneumonia and influenza in the 50-64 year old population in Spain (1999-2002). Hum Vaccin 2: 181-184.
12. Soyseth V, Brekke PH, Smith P, Omland T (2007) Statin use is associated with reduced mortality in COPD. Eur Respir J 29: 279-283.
13. Vaz Fragoso CA, Concato J, McAvay G, Van Ness PH, Gill TM (2012) Respiratory impairment and COPD hospitalisation in older persons: A competing risk analysis. Eur Respir J 40: 37-44.
14. Wang MT, Lo YW, Tsai CL, Chang LC, Malone DC, et al. (2013) Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 126: 598-606 e592.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40: 373-383.
16. Fairman K, Motheral B (2000) Evaluating Medication Adherence: Which Measure Is Right for Your Program? J Managed Care Pharm 6: 499-504.
17. Ward A, Ishak K, Proskorovsky I, Caro J (2006) Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: A retrospective database study. Clin Ther 28: 1912-1921.
18. Marti S, Munoz X, Rios J, Morell F, Ferrer J (2006) Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J 27: 689-696.
19. Casanova C, Cote C, De Torres JP, Aguirre-Jaime A, Marin JM, et al. (2005) Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 591-597.
20. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB (2008) Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 63: 301-305.
21. Ranieri P, Bianchetti A, Margiotta A, Virgillo A, Clini EM, et al. (2008) Predictors of 6-month mortality in elderly patients with mild chronic obstructive pulmonary disease discharged from a medical ward after acute nonacidotic exacerbation. J Am Geriatr Soc 56: 909-913.
22. Wildman MJ, Sanderson C, Groves J, Reeves BC, Ayres J, et al. (2009) Predicting mortality for patients with exacerbations of COPD and Asthma in the COPD and Asthma Outcome Study (CAOS). QJM 102: 389-399.
23. Patil SP, Krishnan JA, Lechtzin N, Diette GB (2003) In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 163: 1180-1186.
24. Mohan A, Premanand R, Reddy LN, Rao MH, Sharma SK, et al. (2006) Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit. BMC Pulm Med 6: 27.
25. Cheng Y, Borrego ME, Frost FJ, Petersen H, Raisch DW (2014) Predictors for mortality in hospitalized patients with chronic obstructive pulmonary disease. Springerplus 3: 359.
26. Almagro P, Calbo E, Ochoa De Echaguen A, Barreiro B, Quintana S, et al. (2002) Mortality after hospitalization for COPD. Chest 121: 1441-1448.
27. Fabbri LM, Luppi F, Beghe B, Rabe KF (2008) Complex chronic comorbidities of COPD. Eur Respir J 31: 204-212.
28. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009.
29. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, et al. (2000) Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283: 1295-1302.
30. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, et al. (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet 374: 1840-1848.
31. Young RP, Hopkins R, Eaton TE (2009) Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: A review of the evidence. Postgrad Med J 85: 414-421.
32. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, et al. (2006) Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47: 2554-2560.
33. Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, et al. (2014) Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 370: 2201-2210.
34. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E (2005) Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 98: 493-497.
35. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ (2011) Effect of beta blockers in treatment of chronic obstructive pulmonary disease: A retrospective cohort study. BMJ 342: D2549.
36. Andreas S, Anker SD, Scanlon PD, Somers VK (2005) Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 128: 3618-3624.
37. Lipworth BJ, Williamson PA (2009) Beta blockers for asthma: A double-edged sword. Lancet 373: 104-105.
38. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS (2012) Renin-angiotensin system blockade: A novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond) 123: 487-498.
39. Kaparianos A, Argyropoulou E (2011) Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: Their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem 18: 3506-3515.
40. Wong MH, Chapin OC, Johnson MD (2012) LPS-stimulated cytokine production in type I cells is modulated by the renin-angiotensin system. Am J Respir Cell Mol Biol 46: 641-650.
41. Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA, et al. (2006) Angiotensin II blockers in obstructive pulmonary disease: A randomised controlled trial. Eur Respir J 27: 972-979.
42. Rivera-Fernandez R, Navarrete-Navarro P, Fernandez-Mondejar E, Rodriguez-Elvira M, Guerrero-Lopez F, et al. (2006) Six-year mortality and quality of life in critically ill patients with chronic obstructive pulmonary disease. Crit Care Med 34: 2317-2324.
43. Ai-Ping C, Lee KH, Lim TK (2005) In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: A retrospective study. Chest 128: 518-524.
44. Steer J, Gibson GJ, Bourke SC (2010) Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM 103: 817-829.
45. Roche N, Zureik M, Soussan D, Neukirch F, Perrotin D (2008) Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. Eur Respir J 32: 953-961.
46. Yang YW, Chen YH, Wang KH, Wang CY, Lin HW (2011) Risk of herpes zoster among patients with chronic obstructive pulmonary disease: A population-based study. CMAJ 183: E275-280.
47. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, et al. (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363: 1128-1138.
48. Chandra D, Guntupalli KK, Guleria R (2007) Hypotension is a predictor of mortality in acute exacerbations of chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 49: 13-18